Understanding the pharmacokinetic and pharmacodynamic properties of darolutamide and other next-generation androgen receptor inhibitors may help in decision making for these drugs.

Darolutamide is distributed to the brain only to a small extent, so its potential for seizures is limited.

Darolutamide has a low potential for drug–drug interactions but may significantly alter BCRP substrates exposure.